2024-516577-76-00
Completed
Phase 1/2
A phase I/II study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of FR104, a novel antagonist pegylated anti-CD28 Fab’ antibody fragment in de novo renal transplant patients - FIRsT
Centre Hospitalier Universitaire De Nantes1 site in 1 country10 target enrollmentAugust 14, 2024
Overview
- Phase
- Phase 1/2
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Centre Hospitalier Universitaire De Nantes
- Enrollment
- 10
- Locations
- 1
- Status
- Completed
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Coordonnateur
Scientific
Centre Hospitalier Universitaire De Nantes
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Not specified
Study Sites (1)
Loading locations...
Similar Trials
Active, not recruiting
Not Applicable
SHORE-studyEUCTR2010-020171-23-DE4SC AG80
Active, not recruiting
Phase 1
A safety and efficacy study of the drug BGB-290 in combination with radiation therapy and/or temozolomide (TMZ) in patients with brain cancer.glioblastomaTherapeutic area: Diseases [C] - Cancer [C04]EUCTR2017-001554-33-NLBeiGene USA, Inc.300
Completed
Phase 1
A phase I/IIa study to assess safety, tolerability, pharmacokinetic, pharmacodynamic effects and exploratory efficacy of two doses of AGMG0201 in patients with essential hypertension.Essential HypertensionCardiovascular - HypertensionACTRN12617001192370Avance Clinical Pty Ltd24
Completed
Not Applicable
A phase I study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple-dose subcutaneous and intravenous administration of OMS721 in healthy subjectsautoimmune diseases10003816NL-OMON42466Omeros Corporation24
Completed
Phase 1
Inhalation of Leukotriene B4 (LTB4) in patients suffering from BronchiectasisACTRN12614001199606TB4 Sweden AB30